AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2024
Mar 26, 2024
33483_dirs_2024-03-26_ac3e1c5e-2b88-48df-9513-5505755287eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-03-26
Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-26 | Common Stock | M | 1970443 | $1.46 | Acquired | 33043849 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-26 | Warrant (Right to Buy) | $1.46 | M | 1970443 | Disposed | 2024-12-23 | Common Stock (1970443) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 7471625 | Direct |
| Common Stock | 86418 | Indirect |
Footnotes
F1: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.
More from Cartesian Therapeutics, Inc.
Capital/Financing Update
2026
May 26
Share Issue/Capital Change
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Earnings Release
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Board/Management Information
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Investor Presentation
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8